Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042384 (vasculitis)
 20,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

B27 and the CREG antigens (-7, -27, -40, -42, and -22) have been shown to be related to the spondyloarthropathies. We have studied the frequency distribution of these antigens in patients with RA. Two hundred ninety-six patients with either classical or definitive RA by ARA criteria were studied: 199 were whites and 97 were blacks. Appropriate local control subjects were also studied (242 whites and 283 blacks). In the white RA patients 48.7% possessed a CREG antigen (97 of 199) while in the black patients 28.9% were CREG positive (28 of 97). In the white control subjects, 45.9% had a CREG antigen and 31.4% for the black control subjects. The relationship between CREG antigens and disease expression was compared using clinical, demographic, radiologic, and therapeutic parameters. For the white group there was no difference in the age and sex, disease duration, functional capacity, anatomic grading, C/M ratio, seropositivity, frequency of extraarticular manifestations (subcutaneous nodules, vasculitis, sicca symptoms, pleuropulmonary, or pericardial disease), frequency of remittive therapy, and toxicity to chrysotherapy. For the blacks all parameters were comparable except for a decrease in the frequency of extraarticular manifestations among the CREG-positive patients (21.4 vs. 46.4%) which is significant (p less than 0.05). Our data show no significant differences in the frequency of the CREG antigens in either blacks or whites with RA as compared to normal subjects. However, a possible sparing of some of the extraarticular manifestations of the disease appears to associate with the CREG antigens.
 ...
PMID:CREG antigens differentially influence expression of extraarticular manifestations in whites and blacks with rheumatoid arthritis. 667 12

In order to clarify the significance of rheumatoid arthritis (RA) as a cause of cardiac compression, we scrutinized pericardiectomy files of 47 patients over a ten-year period at two university hospitals in Finland. Five patients with RA were found. All the patients with RA were men with seropositive disease and subcutaneous rheumatoid nodules. Two of the patients had pulmonary fibrosis, one had cutaneous vasculitis and three had had rheumatoid pleurisy. There was a mean delay of 10 months from the first cardiac symptom to the diagnosis of cardiac compression, the most common misdiagnosis being primarily a liver disease. On the basis of clinical and operative data, four out of the five patients had constrictive pericarditis and one had an effusive-constrictive form of the disease. The histopathological findings in all cases were consistent with chronic fibrosing pericarditis. A follow-up of seven to seventeen years of four patients has not revealed any signs of recurrent pericardial disease. Our results demonstrate that RA is an important aetiological factor for cardiac compression. The long-term outcome of this manifestation seems to be good after pericardiectomy.
 ...
PMID:Rheumatoid arthritis as a cause of cardiac compression. Favourable long-term outcome of pericardiectomy. 835 78

Cardiac abnormalities has been receiving increased attention in patients with systemic lupus erythematosus (SLE). Cardiovascular system involvement has been found to have a substantial effect on mortality and morbidity in patients with SLE [1]. Recent diagnostic methods using echocardiography examination have allowed the delineation of cardiac manifestations such as myocarditis and myocardial dysfunction, valvular disease, pericardial disease or pulmonary hypertension. A report of two cases is presented: 23-year-old man with acute myocarditis with left ventricular failure and pulmonary oedema as a initial presentation of active SLE, and 51-year-old woman with SLE, antiphospholipid antibodies, with history of cerebral embolic infarction, TIA and venous thrombosis and with mitral valvular dysfunction in course of nonbacterial thrombotic endocarditis. Pulmonary hypertension has been recognised in both patients probably as a result of vasculaopathy and intimal proliferation, vasculitis, thromboembolic disease or parenchymal lung disease in SLE. Recent advances in diagnosis and treatment have substantially improved the prognosis of patients with systemic lupus erythematosus and cardiovascular system involvement [2].
 ...
PMID:[Cardiovascular involvement in systemic lupus erythematosus: report of two cases]. 1287 81

Inflammatory disorders of the cardiovascular system can affect the myocardium, pericardium, or vessel walls. Patients with myocardial and pericardial disease may present with chest pain, palpitations, and shortness of breath, symptoms resembling myocardial ischemia or infarction. The manifestations of vasculitis may include fever, weight loss, and fatigue, mimicking infectious or malignant processes. Because of the difficulty of differentiating these disease processes, patients frequently undergo multiple diagnostic examinations before obtaining a final diagnosis of myocarditis, pericarditis, or vasculitis. Computed tomography (CT) and magnetic resonance imaging play important roles in the assessment of structural abnormalities of the cardiovascular system, and combined positron emission tomography (PET) and CT may depict inflammatory processes before structural changes occur. Familiarity with the PET/CT appearances of inflammatory processes in the myocardium, pericardium, and vessels is important for accurate and prompt diagnosis.
 ...
PMID:Utility of FDG PET/CT in inflammatory cardiovascular disease. 2191 44

Cardiovascular toxicities associated with immune checkpoint inhibitors (ICIs) have been reported in case series but have been underappreciated due to their recent emergence, difficulties in diagnosis and non-specific clinical manifestations. ICIs are antibodies that block negative regulators of the T cell immune response, including cytotoxic T lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and PD-1 ligand (PD-L1). While ICIs have introduced a significant mortality benefit in several cancer types, the augmented immune response has led to a range of immune-related toxicities, including cardiovascular toxicity. ICI-associated myocarditis often presents with arrhythmias, may co-exist with myositis and myasthenia gravis, can be severe, and portends a poor prognosis. In addition, pericardial disease, vasculitis, including temporal arteritis, and non-inflammatory heart failure, have been recently described as immune-related toxicities from ICI. This narrative review describes the epidemiology, diagnosis, pathophysiology, and treatment of cardiovascular toxicities of ICI therapy, highlighting recent developments in the field in the past year.
 ...
PMID:Cardiovascular toxicities associated with immune checkpoint inhibitors. 3095 59